MedTrace Logo

Ataraxis Real-World Clinical Outcomes Registry Linking AI-Based Pathology Scores to Patient Outcomes

NCT07706842 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2026-07-16

No results posted yet for this study

Summary

The ARC Registry is a large-scale, multi-site, prospective, observational registry. All patients with a solid tumor malignancy who receive Ataraxis testing as part of routine clinical care are eligible for enrollment, which will link Ataraxis test results with short- and long-term patient outcomes to evaluate the real-world performance and clinical utility of Ataraxis tests. The ARC Registry utilizes an adaptable design, where additional Sponsor-led analyses and investigator-initiated ancillary studies can be added after the initial study is opened.

Conditions

Interventions

DIAGNOSTIC_TEST

Ataraxis testing

Ataraxis AI's digital pathology-based artificial intelligence (AI) testing, ordered as part of routine clinical care.

Sponsors & Collaborators

  • Ataraxis AI, Inc.

    lead INDUSTRY

Principal Investigators

  • Jan Witowski, MD, PhD · Ataraxis AI

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2038-08-31
Completion
2038-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07706842 on ClinicalTrials.gov